Praising President Donald Trump’s recent executive order to redirect the previous administration’s energy regulations, a spokesman for the grassroots Americans for Prosperity (AFP) has issued a statement of support. Read More »
Sanofi and Regeneron Pharmaceuticals recently presented Phase 3 Chronos study results at the late-breaking oral abstract session of the Annual Meeting of the American Academy of Dermatology. Read More »
Alcon, a division of Novartis, has received approval from the U.S. Food and Drug Administration for its AcrySof IQ ReSTOR +2.5 Multifocal Toric intraocular lens with ActiveFocus optical design. The product was made for patients with an astigmatism and presbyopia who want to treat them both at the same time with cataract surgery. Read More »
Genentech's Ocrevus, the only medicine capable of treating both relapsing and primary progressive forms of multiple sclerosis, has been approved by the U.S. Food and Drug Administration. Read More »
Pharmacists and the difficult balance they must keep between patients suffering from chronic pain and the prevalence opioid abuse was the topic of a recent special issue of the Journal of the American Pharmacists Association Read More »
McKesson, the platinum sponsor of CBI’s Formulary, Co-Pay and Access Summit is presenting a new approach to patient-centric behavioral coaching with the overall goal of improving adherence despite affordability and other barriers. Read More »
Prescription drug costs battles are far from over as PCMA calls for the drug lobby to stop deflecting blame in an effort to maintain profit margins. Read More »
Biologics Inc., which is owned by McKesson Specialty Health, has been chosen as the exclusive specialty pharmacy provider for BAVENCIO (avelumab). Read More »
Daiichi Sankyo Inc.has sold its pharmaceutical packaging plant in Bethlehem, Pennsylvania to Sharp Packaging Services, a division of UDG Healthcare. Read More »
The U.S. Food and Drug Administration (FDA) has granted Bristol-Myers Squibb Co. a priority review for the company’s Opdivo Biologics License Application. Read More »
Walgreens and Prime Therapeutics LLC merge to offer specialty pharmacy and mail services Read More »
AbbVie's supplemental new drug application for ibrutinib, a product for treating chronic graft vs. host disease (cGVHD) after failure of one or more lines of systemic therapy, has received FDA approval. Read More »
Daiichi Sankyo Inc. recently announced the enrollment of the first person for its Eliminate-AF study. Read More »
Bracco Imaging has invested in PHS Technologies Group to solidify Bracco's role in the industry and increase the scope of its portfolio software applications related to dose management. Read More »
Pfizer Inc.'s supplemental New Drug Application (sNDA) for Ibrance, its first-in-class cyclin dependent kinase 4/6 (CDK 4/6) inhibitor, has been approved by the U.S. Food and Drug Administration. Read More »
Panacea Pharmaceuticals Inc. presented its paper, "Improved Detection of Cancer Specific Serum Exosomal Aspartyl (Asparaginyl) beta Hydroxylase," and its findings on the company's multi-cancer HAAH exosome detection assay during the annual American Association for Cancer Research meeting in Washington, D.C. April 1-5. Read More »
Popularly known for its ability to enhance facial appearance cosmetically, Botox is now under scrutiny for its possible application for treating major depressive disorder, based on data from a study undertaken by Allergan. Read More »
The paper "Radioimmunotherapy for Acute Myeloid Leukemia Targeting Human Aspartyl (Asparaginyl) β-Hydroxylase” was presented at the American Association for Cancer Research (AACR) meeting by Panacea Pharmaceuticals on April 3. Read More »
Teaming up to enhance North Carolina’s public health outcomes, Purdue Pharma of Stamford, Connecticut; nationwide Project Lazarus; and Safe Kids North Carolina recently entered a three-way collaboration via the North Carolina Disposal Initiative (NCDI). Read More »
To treat some of Huntington disease’s harshest symptoms and help restore quality of life to those suffering from the rare, fatal neurodegenerative disease, the U.S. Food and Drug Administration recently approved a medication created by Teva Pharmaceutical Industries. Read More »
Alerts Sign-up
